Item 7.01 Regulation FD Disclosure
On January 11, 2022, Cardiff Oncology, Inc. (the "Company") issued a press
release announcing announced new data from its lead clinical program evaluating
onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for
second-line treatment of patients with KRAS-mutated metastatic colorectal cancer
(mCRC). The data will be presented as a poster by Dr. Heinz-Josef Lenz,
principal investigator, USC Norris Comprehensive Cancer Center, at the American
Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) on
Saturday, January 22, 2022. A copy of the press release is furnished as Exhibit
99.1 to this Form 8-K. In addition, the Company plans to make a presentation to
investors at 5:00 pm ET on January 18, 2022 with the Corporate Presentation
furnished as Exhibit 99.2 to this Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K is being furnished and shall not be deemed "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
99.1 Press Release of Cardiff Oncology, Inc. dated January 18, 2022
99.2 Corporate Presentation dated January 18, 2022
© Edgar Online, source Glimpses
CARDIFF ONCOLOGY, INC. 
